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ABSTRACT 
 
CECILY LEHMAN: The effects of estradiol on insulin concentration in response to an acute 
bout of exercise. 
(Under the direction of Anthony C. Hackney, PhD, DSc) 
 
The purpose of this study was to determine the influence of changes in circulating 
estradiol levels on the insulin response to an acute bout of exercise, in college age women 
who were not using hormonal contraceptives.  Ten eumenorrheic women completed exercise 
sessions (60 minutes, 65% of VO2max) in the mid-follicular (days 3 – 7; low estradiol levels) 
and mid-luteal (days 20 – 25; high estradiol levels) phases of their menstrual cycle.  Blood 
samples were taken pre-exercise, immediately post-exercise, and 30 minutes into recovery.  
Results indicate that there is not a significant change in resting or exercise insulin levels 
during the low and high estradiol phases of the menstrual cycle (p = 0.415).  In addition, the 
added stress of exercise does not cause a significantly different percentage change (i.e., level 
of decrease) in insulin between the low and high estradiol phases of the menstrual cycle (p = 
0.494).  
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CHAPTER I 
Introduction 
Insulin is a polypeptide hormone secreted from the beta-cells of the pancreas. At rest, 
usually postprandial, insulin stimulates glucose uptake, resulting in a decrease in blood 
glucose levels (1).  As blood glucose decreases, insulin release from the pancreas is inhibited 
through a feedback mechanism, allowing the level of glucose in the blood to be tightly 
regulated (2).  Insulin promotes glycogen synthesis in muscle tissue, and fat synthesis in 
adipose tissue, creating energy stores within the body (3).  Glucagon is the antagonistic 
hormonal counterpart to insulin, promoting glycogenolysis and gluconeogenesis.  When 
comparing the two hormones, a high Insulin/Glucagon (I/G) ratio usually causes a decrease 
in blood glucose, while a low I/G ratio usually causes an increase in blood glucose (1).  
 During exercise the release of insulin is inhibited by the sympathetic nervous system 
in order to maintain adequate concentrations of blood glucose; i.e., to provide a means by 
which non-insulin dependent glucose uptake can be increased at skeletal muscle (4).  The 
drop in insulin concentration decreases the I/G ratio and promotes the effects of glucagon, 
thereby increasing blood glucose. The decrease in insulin concentration with the onset of 
exercise has been well established (5, 6, 7).  It has also been demonstrated that one hour of 
moderate exercise can immediately increase insulin sensitivity and responsiveness in 
untrained subjects, and the effects can last for 48 hours after the exercise bout (6).  Therefore, 
exercise is a beneficial therapy for metabolic diseases, like type two diabetes mellitus, where 
the insulin response has been corrupted. 
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 Estradiol (E2) is an 18-carbon steroid hormone derived from cholesterol and is the 
main estrogen secreted by the ovaries in females (1).  Estradiol helps to control ovulation, 
menstruation, and pregnancy, but can also have influence on blood vessels, bones, lungs, 
liver, intestines and metabolism (2).  In eumenorrheic women, E2 levels vary greatly over the 
course of the menstrual cycle, with concentrations being lower in the follicular phase (days 1 
– 14), and increasing during the luteal phase (days 15 – 28) (1).  E2 is known to have many 
metabolic actions on a multitude of tissues (8). In general, the impact on energy metabolism 
is to reduce reliance on carbohydrate as an energy source while enhancing lipid reliance (8, 
9).  Estradiol brings about these actions by direct effects on tissues through interactions with 
E2 receptors, and indirectly by it actions on other hormones in the endocrine system. For 
example, relative to this last point, elevated E2 levels promote enhanced growth hormone 
release from the anterior pituitary, and growth hormone induces increased lipolysis activity 
(10).  Figure 1 schematically depicts some of the direct and indirect physiologic means by 
which E2 mediates these effects on energy metabolism (8).   
One of the means by which E2 indirectly affects energy metabolism is by altering the 
actions of the hormone insulin.  While there is evidence indicating that E2 has transient 
effects on insulin, the results from research studies are notuniversally in agreement.  For 
example, some studies have indicated an increase in resting insulin, specifically in the luteal 
phase of the menstrual cycle (high E2 levels), while other studies have shown no difference in 
insulin whether E2 concentration is high or low (8, 11, 12). Similarly, studies on the effects of 
E2 on the insulin response to an acute bout of exercise have also produced mixed results (11, 
13, 14).  Bonen et al. (11) observed similar concentrations of insulin between the follicular 
and luteal phases of the menstrual cycle.  Lavoie et al. (13) observed a decreased 
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concentration of insulin in the luteal phase of the menstrual cycle.  Finally, Hackney et al. 
(14) observed an increased concentration of insulin in the luteal phase of the menstrual cycle.  
The limited number of studies examining the issue of E2 on insulin (especially relative to 
exercise), and the contradictory nature of findings, suggests more research is needed to create 
a better understanding of the hormonal interactions between E2 and insulin during exercise. 
Therefore the present study was proposed. 
 
Taken from: Bunt J.  Metabolic actions of estradiol: significance for acute and chronic 
exercise responses.  Med Sci Sports Exerc.  1990; 22(3): 286-290. 
 
Purpose of the Study: 
The purpose of this study was to determine the influence of changes in circulating E2 
levels on the insulin response to an acute bout of exercise in college age women, who were 
not using hormonal contraceptives.  Varying levels of E2 were induced by exercising subjects 
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during the mid-follicular (low E2) and mid-luteal (high E2) phases of their menstrual cycles.  
This study required each participant to make three visits to the laboratory.  The initial visit 
was an orientation and maximal oxygen uptake (VO2max) test.  The following two sessions 
(session I and II) were testing days and were scheduled during the mid-follicular (low E2) 
and mid-luteal (high E2) phases of the menstrual cycle.  During sessions I and II, participants 
completed 60 minutes of treadmill exercise at 65% of their predetermined VO2max (enough 
time and intensity to illicit a change in insulin responsiveness based on previous research)(6).  
Blood samples were taken at baseline, immediately post-exercise, and 30 minutes into 
recovery to determine E2 and insulin concentrations.   
Research Questions: 
1. Was there a significant difference in blood insulin concentrations (µIU/mL) 
during the mid-follicular phase when compared to blood insulin levels during the 
mid-luteal phase? 
a. Was there a significant difference in insulin concentration at baseline 
between the mid-follicular phase and mid-luteal phase? 
b. Was there a significant difference in insulin concentration immediately 
post-exercise between the mid-follicular phase and mid-luteal phase? 
c. Was there a significant difference in insulin concentration 30 minutes into 
recovery between the mid-follicular phase and mid-luteal phase? 
2. Did the added stress of exercise cause a significant change in relative (percentage, 
%) blood insulin concentrations when comparing insulin concentrations pre- and 
post-exercise during the mid-follicular phase to insulin concentrations pre- and 
post-exercise during the mid-luteal phase? 
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a. Was there a significant percent change in relative blood insulin 
concentration between baseline and immediately post-exercise when 
comparing the mid-follicular phase to the mid-luteal phase? 
b. Was there a significant percent change in relative blood insulin 
concentration between baseline and 30 minutes into recovery when 
comparing the mid-follicular phase to the mid-luteal phase? 
Research Hypotheses: 
1. There is a significant difference in blood insulin levels during the mid-follicular 
phase when compared to blood insulin levels during the mid-luteal phase. 
a. Insulin concentration at baseline is significantly higher during the mid-
luteal phase compared to the mid-follicular phase. 
b. Insulin concentration immediately post-exercise is significantly higher 
during the mid-luteal phase compared to the mid-follicular phase. 
c. Insulin concentration 30 minutes into recovery is significantly higher 
during the mid-luteal phase compared to the mid-follicular phase. 
2. The added stress of exercise did not cause a significant change in blood insulin 
levels when comparing insulin concentrations pre- and post-exercise during the 
mid-follicular phase to insulin concentrations pre- and post-exercise during the 
mid-luteal phase. 
a. There is no significant percent change in insulin concentration between 
baseline and immediately post-exercise when comparing the mid-follicular 
phase to the mid-luteal phase. 
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b. There is no significant percent change in insulin concentration between 
baseline and 30 minutes into recovery when comparing the mid-follicular 
phase to the mid-luteal phase. 
Definition of Terms: 
Estrogen (E2): an 18-carbon steroid secreted mainly from the ovaries, the major  
estrogen is estradiol.  Estrogen concentrations in the blood vary dramatically over the 
menstrual cycle with levels being lower in the mid-follicular phase and increasing in 
the mid-luteal phase (1).  Estrogen status can be linked to changes in lipid and 
carbohydrate metabolism (8). 
Insulin: a polypeptide hormone secreted from the cells of the pancreas.  Insulin  
stimulates glucose uptake throughout the body, resulting in a decrease in blood 
glucose levels.  Exercise decreases insulin concentration in the blood (1) 
Mid-follicular phase: Days 3 – 7 of the menstrual cycle, E2 levels in the blood are low (1) 
Mid-luteal phase: Days 20 – 25 of the menstrual cycle, E2 levels in the blood are high (1) 
Assumptions: 
1. Subjects were honest about use of hormonal contraceptives and medications. 
2. Subjects were not pregnant or trying to become pregnant.  Pregnancy would alter the 
normal menstrual cycle E2 response. 
3. Subjects complied with exercise and dietary guidelines before exercise sessions. 
Delimitations: 
1. Healthy, recreationally active, premenopausal women between ages 18 – 30. 
2. Subjects had been eumenorrheic for six months prior to the investigation. 
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3. Subjects were not using hormonal contraceptives or had not used any other hormonal 
therapy for six months prior to the study. 
4. Subjects were not taking insulin or other medications that may affect the insulin 
response. 
Limitations: 
1. Subjects consisted of only eumenorrheic women abstaining from hormonal 
contraceptives; consequently the results are not applicable to men, amenorrheic 
women, postmenopausal women, and women taking hormonal contraceptives or 
hormone therapy. 
2. The results are not applicable to persons who take insulin or have metabolic disorders 
such as diabetes. 
3. Exercise sessions consisted of running so results may not be applicable to other forms 
of exercise.   
Significance of Study: 
The results of this study will add to the limited knowledge of the effects of E2 on insulin 
concentrations in response to an acute bout of exercise.  An increased knowledge of such 
effects in response to an acute bout of exercise can have significance in further understanding 
the metabolic role E2 has on insulin, energy use, and the development of metabolic disease.  
Unfortunately, additional inquires cannot be answered without increased familiarity of the 
interactions between E2 and insulin in a young healthy premenopausal population.  Increased 
understanding of the interactions between E2 and insulin in a young healthy premenopausal 
population may lead to understanding the E2 and insulin interaction in postmenopausal 
women.  If E2 and insulin interact in a menstruating population, then as E2 concentrations 
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decrease with age and menopause begins, insulin concentrations should be affected.  Due to 
the interaction of E2 and insulin, and the variations of hormone concentrations with age, 
exercise prescriptions and nutrition recommendations may need to be altered to meet the 
changing demands of the aging female. 
 
 
 
 
CHAPTER II 
Review of Literature 
This chapter is divided into seven sections. The first section is a brief summary of 
insulin and its effects on the body during rest.  The second section gives an overview of 
studies documenting the interactive effects of insulin and exercise.  Within the second section 
the effects of insulin during exercise are discussed in an acute bout of exercise in a healthy 
untrained population; then the effects of insulin and training are discussed.  The third section 
is a brief summary of E2 its effects on the body during rest.  The fourth section gives an 
overview of studies documenting the interactive effects of insulinand exercise.  Within the 
fourth section the effects of E2 during exercise are discussed in an acute bout of exercise 
focusing on women and comparing women and men; then the effects of E2 during exercise 
are discussed in women who are habitually active.  The fifth section is a brief summary of the 
interaction of insulin and E2.  The sixth section gives an overview of studies documenting the 
interactive effects of E2, insulin, and exercise.  Within the sixth section the interactive effects 
of E2, insulin, and exercise are discussed in acute bouts of exercise varying in time from 60 
minutes to 120 minutes, and varying in intensity from 50% to 80% of VO2max.  The sixth 
section moves from exercise without a glucose load, to exercise with a glucose load, and 
finally exercise comparing a fasted state to a glucose loaded state.  The seventh and final 
section is a summary of the chapter. 
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Insulin 
 Insulin is a polypeptide hormone secreted from the beta-cells of the pancreas. At rest, 
the consumption of nutrients causes a release of insulin, stimulating glucose uptake into 
different body tissues (15).  Insulin promotes glycogen synthesis in muscle tissue and fat 
synthesis in adipose tissue, creating energy stores within the body (3).  Ultimately the actions 
of insulin result in a decrease in blood glucose levels (1).  As blood glucose decreases, 
insulin release from the pancreas is inhibited through a feedback mechanism, allowing the 
level of glucose in the blood to be tightly regulated (2).  Insulin concentrations in the blood 
never reach zero. Even during fasting conditions there is still a small concentration of insulin 
in the blood stream (15).  The antagonistic hormonal counterpart to insulin is glucagon, 
which promotes glycogenolysis and gluconeogenesis.  When comparing the two hormones, a 
high Insulin/Glucagon (I/G) ratio usually causes a decrease in blood glucose, while a low I/G 
ratio usually causes an increase in blood glucose (1).  
Insulin and Exercise 
 To determine if insulin and exercise had an additive or synergistic effect, DeFronzo et 
al. (5) compared 10 healthy males, who had no history of diabetes and had completed a 12 – 
24 hour fast, using four separate study protocols. Subjects all maintained a similar diet for 
three days leading up to each laboratory visit.  Study one looked at the effects of insulin 
alone using an insulin clamp technique.  Study two looked at the effects of exercise alone on 
glucose uptake after 30 minutes of cycling at 40% VO2max.  Study three combined protocols 
from study one and two.  In study protocol three, subjects underwent the same insulin clamp 
technique as in study protocol one, afterwards subjects then cycled for 30 minutes at 40% 
VO2max.  Study four repeated the protocol in study three, but with additional catheters 
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placed in the femoral artery and femoral vein to monitor glucose activity within the legs.  
Results from all four protocols, indicated that insulin and exercise act synergistically to 
enhance glucose metabolism in skeletal muscle tissue.  
Mikines et al. (6), used euglycemic hyperinsulinemic clamp tests to observe the 
effects of exercise and insulin after one hour of rest, one hour of cycling at 64% VO2max, 
and 48 hours after one hour of cycling at 64% VO2max, in seven untrained healthy males 
without a family history of metabolic disorder or diabetes.  For three days prior to each 
laboratory visit, subjects ate a “weight-maintaining diet” and refrained from strenuous 
physical activity.  Subjects refrained from tobacco and alcohol the day before, and fasted the 
night before each laboratory visit.  Results showed that one hour of exercise increases insulin 
sensitivity and responsiveness in untrained subjects that lasts for 48 hours into recovery from 
the exercise (6).  
  King et al. (7) demonstrated that exercise training increases insulin sensitivity.  
Subjects, five men and four women, were all exercising as least 45 minutes per day, five to 
seven days per week.  Diets were recorded for three days before the first euglycemic 
hyperinsulinemic clamp test, and the diet was repeated for three days before the second 
euglycemic hyperinsulinemic clamp test.  All tests occurred after an overnight fast.  The first 
euglycemic hyperinsulinemic clamp test took place while the subjects were still exercising, 
while the second test took place after the subjects had been physically inactive for 10 days.  
Results indicate after 10 days of physical inactivity, the increased insulin sensitivity that 
accompanies exercise training reverses when exercise stops (7).   
 Although the aforementioned studies have primarily male subjects, the same effects 
of exercise on insulin have been seen in women (4).  During exercise, the release of insulin is 
12 
 
inhibited by the sympathetic nervous system in order to maintain adequate concentrations of 
blood glucose; i.e., to provide a means by which non-insulin dependent glucose uptake can 
be increased at skeletal muscle (4).  The inhibition of insulin release decreases insulin 
concentration in the blood.  However, insulin concentrations in the blood never reach zero 
(15).  Therefore exercise can only force insulin concentration to decrease to the lower limit of 
the normal hormonal range.  This phenomenon is referred to as the “basement effect” (16).  
Estradiol 
E2 is an 18-carbon steroid hormone derived from cholesterol, and is the main estrogen 
secreted by the ovaries in females (1).  E2 helps to control ovulation, menstruation, and 
pregnancy, but can also have influence on blood vessels, bones, lungs, liver, intestines and 
metabolism (2).  E2 varies dramatically over the menstrual cycle, with concentrations being 
lower in the follicular phase (days 1 – 14) and higher in the luteal phase (days 15 – 28) (1).  
Both animal and human model research has shown during rest, E2 can lead to increased 
lipolysis and decreased gluconeogenesis and glycogenolysis (8, 17).   
Estradiol and Exercise 
 Hackney et al. (9) collected data on substrate utilization from nine eumenorrheic 
women performing 30 minutes of running which increased in intensity every 10 minutes 
from 35% VO2max, to 60% VO2max, and finally to 75% VO2max.  Exercise bouts were 
conducted during both the mid-follicular and mid-luteal phases of the menstrual cycle.  
Results showed that during exercise at 35% and 60% of VO2max lipid utilization was 
significantly greater during the mid-luteal phase of the menstrual cycle when E2 is elevated.  
There was no difference between substrate utilization and phase of the menstrual cycle 
during exercise at 75% VO2max.  
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In a study performed by Bailey et al. (18), nine healthy eumenorrheic women, not 
using oral contraceptives, cycled at 70% of peak oxygen uptake (VO2peak) until exhaustion.  
Exercise trials were performed twice during the follicular phase and twice during the luteal 
phase.  Subjects were asked to refrain from caffeine and alcohol 12 hours prior to testing and 
strenuous exercise 24 hours prior to testing.  On the day of exercise testing all subjects were 
fed a standard breakfast at the laboratory.  The purpose of this investigation was to determine 
if E2 influenced the effect of carbohydrate supplementation.  Results indicated that 
carbohydrate supplementation is not influenced by menstrual cycle phase.  It is interesting to 
note that increases in performance measured by duration to exhaustion, due to 
supplementation, were lower in women (11 – 14% increase) when compared to men 
exercising in the same conditions (24 – 32% increase). 
It has been shown that during low to moderate intensity endurance exercise, 35% - 
70% VO2max, women utilize more lipids and fewer carbohydrates for metabolic energy 
when compared to men (19).  The higher levels of E2 in women are associated with a shift in 
energy substrate utilization towards lipids (8).  When E2 levels are experimentally increased 
in men; use of lipids as a substrate during exercise increases, while use of carbohydrates as a 
substrate during exercise decreases (19).  Similar findings have been reported for male rats 
administered estrogens and then exercise trained; the use of lipids as an energy substrate 
increases (17). Furthermore, Hackney (20) performed muscle biopsies before and after 60 
minutes of exercise (70% VO2max) in women at the mid-follicular and mid-luteal points of 
their cycles, and found that muscle glycogen utilization was decreased in the luteal phase. 
This utilization difference was attributed to a greater reliance on lipids as a fuel source.  
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Finally, it has been documented that a negative correlation exists between habitual 
exercise, of moderate intensity, and salivary E2 concentration (21).  A relationship was also 
observed between activity level, E2 concentration, and percentage body fat.  Women who 
reported low activity levels, in both the moderate and high percentage body fat groups, had a 
statistically higher concentration of E2 (21).  Although the authors did not state this, it could 
be hypothesized that habitual exercise increases the sensitivity of E2 which creates a greater 
usage of lipids during exercise. 
Insulin and Estradiol 
 At rest, E2 can inhibit gluconeogenesis and glycogenolysis, reducing the reliance on 
carbohydrate as an energy source while enhancing lipid reliance by increasing the I/G ratio 
(8, 9).  If the I/G ratio is elevated for a prolonged amount of time, insulin sensitivity may 
decrease causing metabolic disorders like type two diabetes mellitus (8). Estradiol brings 
about these actions by direct effects on tissues through interactions with E2 receptors and 
indirectly by its actions on other hormones in the endocrine system. For example, relative to 
this last point, elevated E2 levels promote enhanced growth hormone release from the anterior 
pituitary and growth hormone induces increased lipolysis activity (10).  There is some 
evidence that E2 has direct effects on insulin receptors in adipocytes, however further 
research is merited (22).  In mice, it has been shown that E2 supplementation protects against 
beta cell apoptosis, while in women E2 supplementation improves insulin sensitivity (22).  
Again, Figure 1 schematically depicts some of the direct and indirect physiologic means by 
which E2 mediates these effects on energy metabolism (8).   
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Insulin, Estradiol, and Exercise 
Horton et al. (12) studied glucose kinetics across three phases of the menstrual cycle; 
early follicular, mid-follicular, and mid-luteal.  Thirteen eumenorrheic, active females not 
using oral contraceptives or other hormones, were recruited to cycle for 90 minutes at 50% of 
VO2max.  Diet and exercise were controlled for three days, with an overnight fast the night 
before exercise.  Results showed significantly higher levels of insulin during the first 45 
minutes of exercise in the mid-luteal phase when compared to either point in the follicular 
phase.  Based on other measurements taken, glucose utilization appeared equivalent across 
the menstrual cycle but was coupled with higher levels of insulin within the mid-luteal phase.  
Although not statistically significant, resting levels of insulin were higher during the luteal 
phase then the early follicular or mid-follicular phases. 
In an exercise study performed by Lavoie et al. (13), eumenorrheic, physically active 
females not taking oral contraceptives cycled for 90 minutes at 63% of maximal oxygen 
uptake (VO2max) during the mid-follicular and mid-luteal phases of their menstrual cycles.  
Twenty-four hours before the exercise session, all subjects were restricted to a carbohydrate 
poor diet.  Results indicated lower insulin values during the luteal phase of the menstrual 
cycle; however the concentration difference between phases was not statistically significant.  
In both phases insulin decreased significantly, and in a similar fashion, over the course of the 
exercise bout.  It is interesting to note that these women were starting the exercise session 
glycogen depleted, following a carbohydrate poor diet and an overnight fast.   
In a study conducted by Hackney et al. (14), eight recreationally active, eumenorrheic 
women performed 60 minutes of cycle ergometry at 70% of VO2max after ingesting an oral 
glucose load.  After consuming the glucose load subjects rested for 45 minutes before 
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beginning exercise. Testing occurred in both the follicular and luteal phases of the menstrual 
cycle and both diet and exercise were replicated before testing days.  At the onset of exercise 
insulin decreased similarly in both the follicular and luteal phases.  However, results from 
this study show a statistically significant higher peak insulin response before beginning 
exercise in the luteal phase than in the follicular phase.  Indicating insulin response to a 
glucose challenges differs with the stages of the menstrual cycle. 
 Campbell et al. (23), observed eight endurance trained eumenorrheic women during 
the follicular and luteal phases of the menstrual cycle.  None of the subjects were taking oral 
contraceptives.  Diet was controlled before each exercise trial and no food was allowed the 
morning of a laboratory visit.  Four exercise sessions were conducted consisting of two hours 
of cycling at 70% of VO2max followed by a 4kJ/kg body weight time trial.  Two sessions 
were supplemented with carbohydrate loaded beverages; the other two sessions were 
supplemented with a placebo.  Results indicated that variations in E2 levels throughout the 
menstrual cycle altered exercise metabolism, but that the alterations due to E2 levels dissipate 
with glucose supplementation.  Resting insulin levels were not significantly different 
between trials; however insulin tended to be higher during the luteal phase.   
 Bonen et al. (11) divided 19 eumenorrheic women, not taking oral contraceptives, 
into three groups: a control group, a fasting group, and a glucose-loaded group.  The glucose-
loaded group consumed the glucose load 17 minutes before the onset of exercise.  Subjects 
performed 30 minutes of walking on a treadmill at 40% of VO2max followed by 30 minutes 
of walking up a steep incline at 80% of VO2max.  Exercise sessions were performed during 
both the follicular and luteal phases of the menstrual cycle.  Diet was recorded before the 
first exercise session and repeated before the second exercise session.  Results indicate that 
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when nutritional status is normal, insulin response to exercise is similar in both the follicular 
and luteal phase.  In the glucose loaded group, insulin levels and response to exercise were 
similar between the two phases of the menstrual cycle.  The group of women that fasted had 
significantly higher insulin levels in the luteal phase than in the follicular phase. 
Summary 
In summary, insulin stimulates glucose uptake and promotes glycogen synthesis in 
muscle tissue and fat synthesis in adipose tissue, creating energy stores within the body (1).  
Exercise and insulin work synergistically to enhance the metabolism of glucose, and these 
effects can last up to 48 hours after the bout of exercise (5, 6).  Training increases insulin 
sensitivity but sensitivity will decline with the cessation of exercise (7). 
Estradiol is the main estrogen secreted by the ovaries in females and can lead to 
increased lipolysis, decreased gluconeogenesis and glycogenolysis due, in part, to the 
influence E2 has on increasing the I/G ratio (1, 8).  Research has demonstrated that during 
low to moderate intensity exercise, lipids are oxidized more during the mid-luteal phase of 
the menstrual cycle.  However as exercise intensity increases there is no difference between 
substrate utilization and menstrual cycle phase (9).  At high exercise intensity there is no 
difference in substrate utilization when subjects supplement with carbohydrates (18).  When 
compared to their male counterparts, women utilize lipids more than men during endurance 
exercise due to increased levels of E2 (8, 19).  Finally, physical activity has a negative 
relationship with E2, as activity increases; E2 decreases (21).  
 There is varying information about the effects of E2, insulin, and exercise.  Horton et 
al. (12) found significantly higher levels of insulin during the first 45 minutes of exercise in 
the mid-luteal phase when compared to the follicular phase whereas Lavoie et al. (13) found 
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no significant difference in insulin when comparing different phases of the menstrual cycle.  
Hackney et al. (14) showed a statistically significant higher peak insulin response after an 
oral glucose load but, before beginning exercise in the luteal phase than in the follicular 
phase; indicating insulin response to a glucose challenge differs with the stages of the 
menstrual cycle. However, it was found that at the onset of exercise insulin decreased 
similarly in both the follicular and luteal phases. 
Variations in E2 levels throughout the menstrual cycle alter exercise metabolism, but 
that the alterations due to E2 levels dissipate with glucose supplementation (23).  When 
subjects have not undergone an overnight fast or a pre-exercise glucose load, insulin response 
to exercise is similar in both the follicular and luteal phase.  However, fasted subjects have 
significantly higher resting insulin levels in the luteal phase than in the follicular phase (11). 
 
 
 
 
CHAPTER III 
Methodology 
This study required each participant to make three laboratory visits.  The initial visit 
consisted of an orientation and maximal oxygen uptake (VO2max) test.  The following two 
sessions were submaximal exercise sessions and were scheduled during the mid-follicular 
(low E2) and mid-luteal (high E2) phases of the menstrual cycle.  During the exercise 
sessions, participants completed 60 minutes of treadmill running at 65% of their 
predetermined VO2max.  Blood samples were taken at baseline, immediately post-exercise, 
and 30 minutes into recovery from exercise, to determine E2 and insulin concentrations. 
Subjects 
 Sample size was determined using PS: Power and Sample Size Calculation version 
3.0.43 (Vanderbilt University, Nashville, TN).  An α level of 0.05 required a total of ten 
subjects to achieve a power of 0.80 (β).  Insulin concentrations used in the power calculation 
were taken from a previous investigation performed by Bailey et al. (Bailey et al., 2000).  
Healthy, recreationally active women between the ages of 18 – 30 were recruited.  Subjects 
were premenopausal and eumenorrheic for six months prior to the investigation.  
Eumenorrhea was defined as having a consistent menstrual cycle lasting 24 – 35 days.  
Subjects could not be using hormonal contraceptives or have used any other hormonal 
therapy for six months prior to the study.  Subjects could not be taking insulin or other 
medications that would affect the insulin response. 
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Subjects who were pregnant, taking insulin or any other medications that would affect 
the insulin response, and/or had sustained an injury in the last six months that would limit 
their ability to exercise were excluded from the study.  If any contraindications to exercise 
given by the American College of Sports Medicine (24) were discovered during the physical 
examination or an irregular heart rhythm was discovered during the 12-lead 
electrocardiogram, the subject was excluded from the study and advised to follow–up with 
their physician (Appendix A)(24). 
Instrumentation 
Subject height was measured using a stadiometer (Perspective Enterprises, Portage, 
MI).  Subject mass was measured using a mechanical scale (Detecto, Webb City, MD).  
Electrocardiograms were performed using a Schiller AT 10 Plus EKG unit (Schiller AG, 
Switzerland).  A Lange skinfold caliper (Model 68902, Cambridge Scientific Industries, Inc., 
Cambridge, MA) was used to determine body composition.  All treadmill exercise was 
performed on a Quinton MODEL Q65 treadmill (Cardiac Science Corporation Bothell, WA).  
Expired gas was collected using Parvo Medics TrueMax® 2400 Metabolic System (Parvo 
Medics, Salt Lake City, UT).  Exercise heart rate was monitored using a Polar heart rate 
monitor (Polar Electro Inc., Lake Success, NY).  Rating of perceived exertion (RPE) was 
determined using the Borg scale.  Ovulation was determined using BabyHopes™ Ovulation 
One-Step test strips (BabyHopes.com).  Hematocrit was determined using microcapillary 
tubes (Fisher Scientific International Inc., Hampton, NH), hematocrit tubes were sealed with 
critoseal capillary tube sealant (Krakeler Scientific Inc., Albany, NY), centrifuged with an 
Adams MCHT II microhematocrit centrifuge (Beckton Dickinson, Franklin Lakes, NJ), and 
read with an International Microcapillary Reader (International Equipment Company, 
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Needham Heights, MA).  Hemoglobin was analyzed using the stat-site WT-9 hemoglobin 
meter (Stanbio Laboratory, Boerne, TX).  Lactate was measured using a Lactate+ Analyzer 
(NOVA Biomedical, Waltham, MA) and glucose was measured using a ONE TOUCH 
glucometer (LifeScan, Milpitas, CA).  To separate plasma and serum, an IEC Centra-8R 
refrigerated centrifuge (International Equipment Company, Needham Heights, MA) was 
used.  Estradiol levels were determined using an enzyme-linked immunoabsorbent assay 
(ELISA) (Abnova, Walnut, CA).  Insulin levels were determined also using an ELISA 
(Abnova, Walnut, CA). 
Protocol 
Orientation/Maximal Oxygen Uptake Session 
 Subjects were asked to come to the Applied Physiology Laboratory at the University 
of North Carolina at Chapel Hill.  The study protocol, schedule, inherent benefits, and 
potential risks were explained, and the subject was given an opportunity to ask questions 
before written informed consent was obtained (Appendix B).  The subject then completed the 
Department of Exercise & Sports Science medical history questionnaire and completed a 12-
lead electrocardiogram and physical examination (Appendix C).  Height and body mass were 
obtained and the subject was fitted with a heart rate monitor.  The subject then rested in a 
supine position for 10 minutes to obtain a resting heart rate.  Next the subject was fitted for a 
mouthpiece used to collect expired gases.  A Bruce treadmill protocol test was administered 
to determine VO2max.  Respiratory gases, for indirect calorimetry, and heart rate were 
monitored continuously throughout the test.  Heart rate was recorded at the end of every 
minute, and rate of perceived exertion (RPE) was recorded at the end of every three minute 
stage.  After completion of the VO2max test subjects recovered actively until their heart rate 
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dropped below 120 beats per minute.  Subjects were then asked to passively rest, if no 
adverse responses to exercise were observed the subject was allowed to leave once their heart 
rate decreased below 100 beats per minute. 
 The criteria to determine a maximal response to the VO2max test were: a respiratory 
exchange ratio of 1.1 or greater, reaching age predicted maximal heart rate (±5%), a RPE of 
18 or greater, and a decrease or plateau in VO2 with increased workload.  If all three criteria 
were not met then the test was classified as a VO2peak.  The highest VO2 (max or peak) 
obtained during the test was used to calculate the running speed for the submaximal bouts of 
exercise.  Running speeds to elicit 65% of VO2max were determined using ACSM metabolic 
calculations (24). 
Menstrual Phase Determination 
 Subjects informed the investigator on first day of menses, which was denoted as day 
one.  The forward counting method was used to determine scheduling of the next two 
exercise sessions (25).  The mid-follicular phase was 7 ± 2 days after menses.   The mid-
luteal phase was 20 + 2 days after menses.  The next two exercise sessions were scheduled 
using the onset of menses as day one and counting forward until reaching either the mid-
follicular or mid-luteal phase.  Urinary ovulation testing was used to support the forward 
counting method.  At the end of the orientation session each subject was given an ovulation 
kit and instructions on how to determine the first day of ovulation (Appendix D).  The mid-
follicular and mid-luteal dates were based off of an average 28 day menstrual cycle. If a 
subject had a longer/shorter cycle length adjustments were made in the specific days of 
testing to correspond with the mid-follicular and mid-luteal points. 
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Exercise Sessions 
The subject reported to the laboratory at a similar time for each exercise session. 
Twenty-four hours prior to each of the 60 minute 65% VO2max exercise sessions, the subject 
was asked to drink plenty of water, refrain from caffeine and alcohol, record their food intake 
in a dietary log, and refrain from strenuous exercise.  Two hours prior to the exercise session, 
subjects were asked to refrain from eating or drinking anything besides water.  Upon arrival 
to the laboratory the subject was asked to complete a brief questionnaire to ensure that they 
had complied with physical and dietary guidelines (Appendix E).  Dietary logs were 
reviewed and photo copied.  The original dietary log was kept by the investigator and the 
copy was given back to the subject so they could repeat the same diet 24 hours prior to the 
second exercise session.  Once compliance was established the subject was fitted with a heart 
rate monitor and asked to rest for 10 minutes in a supine position.  After the 10 minutes, 
resting heart rate was recorded, and a three mL blood sample was collected by a certified 
phlebotomist using a venipuncture technique.  The blood samples were placed into K2-EDTA 
blood collection tubes and immediately placed on ice.  The blood samples were used to 
confirm menstrual cycle status and determine resting levels of E2 and insulin, in analyses 
performed later.  After the resting blood draw the subject moved to the treadmill and was 
fitted with a mouthpiece.  Resting respiratory gases were collected for four minutes to 
determine resting VO2.  Next, each subject had 10 minutes to warm-up; five minutes of 
walking on the treadmill and five minutes of stretching.  Following the warm-up the subject 
ran on the treadmill at 0% incline and a speed that elicited 65% of their VO2max.  At six 
minutes, 26 minutes, and 56 minutes the subject was asked to insert the mouthpiece back into 
their mouth for collection of respiratory gases for four minutes.  The four minute sampling 
24 
 
was to ensure running speed was appropriate and to allow adjustments in speed if needed.  
Any adjustments that occurred in the first 60 minute exercise trial were replicated for the 
second trial.  Heart rate and RPE was recorded at 10 minutes, 30 minutes, and 60 minutes. 
The above procedures are depicted in Figure 2.  Throughout the exercise session the subject 
was able to drink water at their convenience, listen to music, and have access to a fan to keep 
cool. 
 At the completion of exercise another three mL blood sample was collected, 
following the same procedure, placed in a K2-EDTA blood collection tube and immediately 
placed on ice.  The subject was then asked to rest in a supine position for 30 minutes.  At the 
end of the 30 minutes of recovery, a final three mL blood sample was collected, following 
the same procedure, placed in a K2-EDTA blood collection tube and immediately placed on 
ice.  After the final blood draw, if no adverse reactions to exercise were observed, the subject 
was released from the laboratory if their heart rate was below 100 beats per minute.  The 
subject repeated the protocol for both the mid-follicular and mid-luteal phases of the 
menstrual cycle. 
Figure 2: Timeline of exercise sessions. 
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Blood Analysis 
Hematocrit 
Resting and post-exercise hematocrit were determined for each exercise session.  
Whole blood was drawn into a heparin treated microcapillary tube, sealed, and centrifuged 
for three minutes at 12,000 revolutions per minutes in a microhematocrit centrifuge.  The 
microcapillary tube was then placed on a hematocrit wheel and the ratio of red blood cells 
within the blood was determined.  Hematocrit measures were performed in triplicate and 
averaged.   
Hemoglobin 
 Resting and post-exercise hemoglobin were determined for each exercise session.  
Twenty-five microliters of whole blood was pipetted onto a slide and analyzed using a 
handheld analyzer.  Hemoglobin measures were performed in triplicate and averaged.   
Plasma Volume 
 To ensure that changes in E2 and insulin were not due to hemoconcentration effects 
alone, plasma volume shifts were calculated using the Dill and Costill method, which uses 
hematocrit and hemoglobin changes (26). The percent changes in the plasma volume shifts 
werecompared to the percent changes in hormonal concentrations following exercise to 
determine the degree of hemoconcentration influence. 
Lactate and Glucose 
 Post-exercise blood samples were analyzed for lactate concentration using a lactate 
analyzer.  Pre-exercise, post-exercise, and recovery blood samples were analyzed for glucose 
concentration using a handheld glucometer. 
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Estradiol and Insulin 
In order to separate the plasma, blood samples were centrifuged at 3000 X g for 15 
minutes at 4° C.  Plasma and serum were removed from the centrifuged samples and frozen 
at -80°C until analyzed later for E2 and insulin concentrations.  E2 and insulin concentrations 
were determined using an ELISA and performed in duplicate.  Specific directions of the 
assay procedures can be found in the appendix (Appendices F and G). 
Statistical Analysis 
 All statistical analyses were done using SPSS statistical software (version 19.0, 
Chicago, IL).  Significance was set a priori at an α < 0.05.  All values were displayed as 
means + standard deviations (SD).  
 To determine if there was significant difference in blood insulin concentrations 
(µIU/mL) during the mid-follicular phase when compared to blood insulin concentrations 
during the mid-luteal phase, a 2x3 (menstrual phase [mid-follicular phase, mid-luteal phase] 
x exercise time [pre-exercise, immediately post-exercise, 30 minutes into recovery]) repeated 
measures model analysis of variance (ANOVA) was used with a Bonferroni post hoc test if a 
significant F-ratio was obtained.  
Insulin concentration percent change from pre-exercise to post-exercise and pre-
exercise to recovery was calculated.To determine if there was a significant difference in 
percent change a 2x2 (menstrual phase [mid-follicular, mid-luteal] x percent change in 
insulin [pre-exercise to immediately post-exercise, pre-exercise to recovery]) repeated 
measures model ANOVA was used with a Bonferroni post hoc test if a significant F-ratio 
was obtained. Figure 3 shows the calculations used to determine percent change in insulin 
concentration.   
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Figure 3: Calculations used to determine percent change in insulin concentration overtime. 
Pre-exercise to immediately post-exercise: 
(([POST] – [PRE]) / [PRE]) x 100 = percent change 
Pre-exercise to 30 minutes into recovery: 
 (([REC] – [PRE]) / [PRE]) x 100 = percent change 
[PRE] – concentration of insulin pre-exercise 
[POST] – concentration of insulin immediately post-exercise 
[REC] – concentration of insulin 30 minutes into recovery 
 
 
 
 
CHAPTER IV 
Results 
Subject Characteristics 
Twelve healthy women were recruited for this study.  Two women were unable to 
complete the study due to personal reasons, leaving ten remaining women who completed all 
aspects of the study.  All subjects met the inclusion criteria of healthy, recreationally active, 
ages 18 – 30, eumenorrheic (≥ six months) prior to the investigation, not using hormonal 
contraceptives or other hormonal therapy, and lastly not taking any insulin or other 
medication that may affect the insulin response.  Subject physical characteristics can be 
found in Table 1.  
Table 1. Subject physical characteristics (n = 10). 
 
Maximal Oxygen Uptake Determination 
The criteria for a maximal response to the VO2max test were: a respiratory exchange 
ratio of 1.1 or greater, reaching age predicted maximal heart rate (± 5%), a RPE of 18 or 
greater, and a decrease or plateau in VO2 with an increased workload.  The VO2max tests 
were stopped due to subject volitional fatigue.  Therefore, only five subjects met all of the 
criteria for a maximal response to the VO2max test.  Since not all of the subjects met all of 
the criteria for a VO2max test, the tests will be referred to from here on out as VO2peak tests.  
 Mean ± SD Range 
Age (yr) 20.0 ± 2.2 18 – 25 
Height (cm) 164.1 ± 5.9 156 – 177 
Mass (kg) 58.7 ± 8.3 43 – 69 
Body Fat (%) 22.3 ± 4.9 13 – 30 
BMI (kg/m2) 21.8 ± 3.1 17.5 – 27.7 
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The mean (± SD) time of the VO2peak tests were 846.5 ± 79.9 seconds. The mean respiratory 
exchange ratio was 1.19 ± 0.05, the mean maximal heart rate was 190 ± 6 bpm, and the mean 
maximal RPE was 18 ± 2.  The mean VO2peak was 50.7 ± 9.0 ml/kg/min with a range of 38 
– 65 ml/kg/min.  
Menstrual Phase Determination 
Each subject was asked to use an ovulation kit to determine ovulation, which was 
used to help determine the dates for the first and second exercise sessions.  The average 
length of the menstrual cycle was 30 ± 3 days.  Testing during the mid-follicular phase, low 
E2 concentrations, occurred on day 5 ± 3 of the menstrual cycle; while testing during the 
mid-luteal phase, high E2 concentrations, occurred on day 24 ± 4 of the menstrual cycle.  
Mean E2 concentration during the mid-follicular phase was 27.04 ± 6.12 pg/ml.  Mean E2 
concentration during the mid-luteal phase was 67.64 ± 21.7 pg/ml.  The difference in E2 
concentrations between the mid-follicular and mid-luteal phases was significant (t = -5.695; p 
< 0.001). 
Exercise Sessions One and Two 
Subjects ran for one hour at 69.7 ± 7.3% of their pre-determined VO2peak during the 
mid-follicular phase and 67.6 ± 7.9% of their pre-determined VO2peak during the mid-luteal 
phase.  VO2 during each exercise session was collected breath by breath but averaged over 15 
second intervals.  However, there was no significant difference in the running intensities 
between exercise sessions (t = 0.617; p = 0.545). 
Heart rates at rest, and all three time points during exercise, were compared between 
both exercise sessions.  Resting HR was 75 ± 13 bpm during the mid-follicular phase and 66 
± 12 bpm during the mid-luteal phase.  There was no significant difference due to the 
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interaction effect of menstrual cycle phase and time point at rest (p = 0.169) and during 
exercise (p = 0.169) on HR between the mid-follicular and mid-luteal phases of the menstrual 
cycle (F = 2.259; p = 0.169).  There was no significant difference found due to the main 
effect for differing phases of the menstrual cycle (F = 0.098, p = 0.762).  There was a 
significant difference due to the main effect of time from rest to the exercise (F = 59.564; p < 
0.001).  A post hoc determined the exercise HR at all measurement points were greater than 
the resting HR (p < 0.001), but not different from one another (p > 0.05).  Heart rates during 
exercise are reported in Table 2.   
The RPE at all three exercise time points were compared between both exercise 
sessions (Table 2).  There was no significant difference due to the interaction effect of 
menstrual phase and time during exercise on RPE between the mid-follicular and mid-luteal 
phases of the menstrual cycle (F = 0.499; p = 0.625).  There was no significant difference 
found due to the main effect for differing phases of the menstrual cycle (F = 3.115; p = 
0.111).  There was a significant difference found due to the main effect of time during 
exercise (F = 8.565; p = 0.010).  A post hoc determined all time points during exercise 
differed significantly from one another (p < 0.05).   
Oxygen uptake averaged over each monitored time point was compared between both 
sessions (Table 2). No significant difference was found due to the interaction effect of 
menstrual cycle phase and time during exercise (F = 1.859; p = 0.225).  No significant 
difference was found due to main effect between phases of the menstrual cycle (F = 2.662; p 
= 0.137). There was a significant difference due to the main effect between time points 
during exercise (F = 82.615; p < 0.001).  A post hoc determined the specific significance 
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occurred when comparing 10 minutes to 60 minutes (p = 0.028) and 30 minutes to 60 
minutes (p = 0.017).   
The RER during the last minute of each monitored time period was compared 
between both exercise sessions (Table 2).  There was not a significant difference found due 
to the interaction effect of menstrual cycle phase and time point during exercise (F = 3.912, p 
= 0.065).  There was not a significant difference found due to the main effect between phases 
of the menstrual cycle (F = 0.06, p = 0.813).  There was a significant difference in RER 
between the different time points during exercise (F= 9.359, p = 0.008).  A post hoc analysis 
determined the specific significance was the RER at 10 minutes (0.91 ± 0.05; 0.90 ± 0.06) 
and 60 minutes (0.88 ± 0.06; 0.86 ± 0.07) as the RER decreased over time (p = 0.004).  
Table 2. The HR, RPE, and VO2 measurements during the one hour exercise sessions at 65% 
of VO2max during the mid-follicular and mid-luteal phases of the menstrual cycle.  The HR, 
RPE, and VO2 were obtained at 10, 30, and 60 minutes during the exercise.   
 10 minutes 30 minutes 60 minutes 
Mid Follicular Heart Rate (bpm) 152 ± 25 160 ± 19 179 ± 19 
RPE 10 ± 2 11 ± 2 13 ± 3 
VO2 (ml/kg/min) 30.90 ± 8.1& 31.52 ± 8.0^ 33.13 ± 8.4&^ 
RER 0.91 ± 0.05& 0.89 ± 0.06 0.88 ± 0.06& 
Mid Luteal Heart Rate (bpm) 155 ± 18 164 ± 18 167 ± 19 
RPE 10 ± 2 12 ± 3 14 ± 3 
VO2 (ml/kg/min) 30.02 ± 8.1& 30.95 ±8.2^ 31.56 ± 8.4&^ 
RER 0.90 ± 0.06& 0.89 ± 0.068 0.86 ± 0.07& 
&Indicates a significance between the 10 minute time point and the 60 minute time point, p < 
0.05; ^Indicates a significance between the 30 minute time point and the 60 minute time 
point, p < 0.05  
 
Lactate and Glucose Response to Exercise 
 Blood lactate concentrations were measured immediately post-exercise.  During the 
mid-follicular phase of the menstrual cycle lactate concentration was 3.0 ± 1.8 mM/L.  
During the mid-luteal phase of the menstrual cycle lactate concentration was 2.4 ± 1.3 
mM/L.  There was no significant difference between post-exercise lactate concentrations 
during the mid-follicular and mid-luteal phases of the menstrual cycle (t = 0.787; p = 0.44). 
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Blood glucose concentrations were measured pre-exercise, immediately post-
exercise, and 30 minutes into recovery, during both the mid-follicular and mid-luteal phases 
of the menstrual cycle exercise sessions.  There was no significant difference found due to 
the interaction effect of menstrual cycle phase and time point (F = 0.179; p = 0.839).  There 
was a significant difference due to menstrual cycle phase (F = 5.731; p = 0.040), with levels 
being slightly greater in the mid-follicular phase.  There was also a significant difference due 
to time point (F = 8.767; p = 0.010). A post hoc determined the specific significance due to 
time point was between post-exercise and recovery (p = 0.007; Table 3).   
Table 3.Blood glucose concentrations (mg/dL) pre-exercise, immediately post-exercise, and 
30 minutes into recovery during the mid-follicular and mid-luteal phases of the menstrual 
cycle.  
 Pre-Exercise 
(mg/dL) 
Post-Exercise 
(mg/dL) 
Recovery 
(mg/dL) 
Mid-follicular 80 ± 13* 86 ± 15*# 78 ± 10*# 
Mid-luteal 75 ± 11* 82 ± 10*# 76 ± 13*# 
*Indicates a significant difference between the mid-follicular and mid-luteal phases of the 
menstrual cycle p < 0.05; #Indicates a significance between post-exercise and the recovery, p 
< 0.05 
 
Insulin Response to Estradiol and Exercise 
Blood insulin concentrations were measured pre-exercise, immediately post-exercise, 
and 30 minutes into recovery during both exercise sessions (see Table 4).  No significant 
difference was found due to the interaction effect of menstrual cycle phase and time point (F 
= 0.984; p = 0.415).  No significant difference was found in insulin concentration due to the 
main effect of menstrual cycle phase (F = 0.247; p = 0.631).  In addition, no significant 
difference was found in insulin concentration due to the main effect of time point (F = 0.685; 
p = 0.532).   
Insulin concentration percent change between pre-exercise to post-exercise and pre-
exercise to recovery was calculated and compared (Table 5).  No significant difference in 
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percent change was found due to the interaction effect of menstrual cycle phase and time 
point (F = 0.507; p = 0.494).  No significant difference was found in percent change due to 
the main effect of menstrual cycle phase (F = 0.861; p = 0.378).  Furthermore, no significant 
difference was found in percent change due to the main effect of time point (F = 0.121; p = 
0.736).   
Table 4. Blood insulin concentrations (µIU/ml) pre-exercise, post-exercise, and 30 minutes 
into recovery during the mid-follicular and mid-luteal phases of the menstrual cycle. 
 Pre-Exercise  
(µIU/ml) 
Post-Exercise  
(µIU/ml) 
Recovery  
(µIU/ml) 
Mid-follicular 3.85 ± 3.14 3.11 ± 1.64 2.69 ± 1.05 
Mid-luteal 3.05 ± 1.18 2.85 ± 1.70 2.97 ± 1.09 
 
Table 5. Insulin concentration percent change between pre-exercise to post-exercise and pre-
exercise to recovery during the mid-follicular and mid-luteal phases of the menstrual cycle.   
 Pre-Exercise to Post-Exercise 
(%) 
Pre-Exercise to Recovery 
(%) 
Mid-follicular -6.31 ± 22.65 -8.13 ± 20.54 
Mid-luteal -1.00 ± 7.56 -0.46 ± 4.96 
 
It should be noted that all hormonal values reported are not corrected for plasma 
volume shifts. This was done because no significant main effect differences (p > 0.05) were 
observed in the magnitude of the plasma volume movement because of menstrual cycle 
phase. Furthermore the data for hematocrit and hemoglobin, from which plasma volume 
shifts are calculated (26), are not reported due to this lack of significance existing. 
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Table 6. Individual measurements of VO2peak, E2, and insulin concentration percent change 
during the mid-follicular and mid-luteal phases of the menstrual cycle for each subject.  
These data are previously reported as mean ± standard deviation in earlier tables. 
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CHAPTER V 
Discussion 
The purpose of this study was to determine the influence of changes in circulating E2 
concentrations on the insulin response to an acute bout of exercise (60 minutes) in college 
age women, who were not using hormonal contraceptives.  Circulating E2 concentrations 
were manipulated by exercise testing subjects at the mid-follicular (low E2) and mid-luteal 
(high E2) phases of the menstrual cycle.  There was not a significant difference in resting 
blood insulin concentration during the mid-follicular phase when compared to the mid-luteal 
phase of the menstrual cycle.  Additionally, the added stress of exercise did not bring about a 
significant change in blood insulin concentrations during the mid-follicular or mid-luteal 
phase of the menstrual cycle.  These findings were contrary to what had been hypothesized. 
 Ten subjects participated in this study which was the goal in order to achieve the pre-
calculated statistical power of 0.80 (β).  The subjects were healthy and met all the inclusion 
criteria.  Furthermore, to the knowledge of the investigator all subjects complied with all of 
the study guidelines. 
The physiological responses of the subjects for HR, VO2, and RPE to the 60 minute 
exercise sessions showed the expected responses to such exercise, and were not significantly 
different between the phases of the menstrual cycle (4).  These latter findings support that 
any observed changes in humoral or hormonal factors were more likely a function of 
menstrual phase and E2 status than variability in exercise intensity. 
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Since the focus of this study was on metabolism, the discussion will be delimited to 
those measured outcomes that relate to energy metabolism as influenced by the hormone 
insulin.  Thus, only blood lactate, glucose and insulin responses are discussed at length. 
Lactate Response to Exercise 
 Blood lactate concentration was measured post-exercise, and no difference was found 
in concentrations between the mid-follicular and mid-luteal phases of the menstrual cycle.  
This is consistent with earlier work where blood lactate was measured either at rest, during 
exercise, or post-exercise (11, 12, 13, 23).  In these studies blood lactate concentration 
significantly increased as exercise time increased but there was not a significant difference in 
blood lactate concentration due to changes in E2 concentration (due to different phases of the 
menstrual cycle). 
 The observed lactate response, however, does not agree with all literature as some 
studies have reported reduced lactate responses to exercise in the luteal phase of the 
menstrual cycle due to an increased lipid mobilization induced by elevated E2 (27, 28).  The 
reason for the difference in findings between these and the present study is unclear, but may 
relate to the intensity of exercise utilized.  The studies finding reduced lactate responses to 
exercise tended to use higher exercise intensities than the current study.  
Glucose Response to Exercise 
 Blood glucose concentration was measured pre-exercise, immediately post-exercise, 
and 30 minutes into recovery.  There was a main effect of menstrual cycle phase, resulting in 
blood glucose concentration being greater in the mid-follicular phase when compared to 
blood glucose concentration measured in the mid-luteal phase (mid-follicular > mid-luteal).  
A significant difference was also found across time of measurement too, as blood glucose 
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concentration between immediately post-exercise and 30 minutes into recovery differed 
(decrease from exercise to recovery).  Previous published results are varied when looking at 
the effects of E2 and exercise on blood glucose concentration.   
In contrast with the current study, Horton et al. (12) found no difference in resting 
glucose values between different phases of the menstrual cycle in eumenorrheic women.  
However, there was a significant difference in the interaction effect of menstrual phase and 
exercise time, with blood glucose concentrations being higher in the first 45 minutes of 
exercise in the mid-luteal phase.  Campbell et al. (23) discovered that in eumenorrheic 
women, menstrual phase had no effect on blood glucose concentration, but there was a 
significant decrease in blood glucose concentration at 120 minutes of exercise when subjects 
were not given a carbohydrate supplement during the exercise.  Lavoie et al. (13) reported a 
significant interaction effect of menstrual phase and exercise time.  In eumenorrheic subjects 
undergoing a 24-hour carbohydrate poor diet and an overnight fast, blood glucose 
concentration significantly decreased after 70 and 90 minutes of exercise in the luteal phase 
of the menstrual cycle but remained constant in the follicular phase of the menstrual cycle.  
Bonen et al. (11), however, reported a significant increase in blood glucose concentration 
during exercise but the change was similar in each phase of the menstrual cycle.  Similar 
findings of Bonen et al. (11) were seen by Hackney et al. (14), who reported a similar blood 
glucose response to exercise and an oral glucose load in each phase of the menstrual cycle.   
In the current study blood glucose decreased from immediately post-exercise into 
recovery, which contradicts some of the earlier results in studies where glucose increased.  
Differences between studies may be due to the time point at which blood sampling occurred.  
In many of the previous studies glucose was measured during exercise not into recovery. 
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At rest and during exercise, E2 has been shown to increase lipolysis and decrease 
gluconeogenesis and glycogenolysis (8, 9, 17, 20).  The increased concentration of E2 and a 
greater reliance on lipids as an energy source during the mid-luteal phase may be the factor 
accounting for the significantly lowered blood glucose concentration in the current study (8).  
This interpretation is supported by the tendency towards a lower exercise lactate (non-
significant) found in the mid-luteal phase as corroborated by other studies (27, 28).  But, at 
this point, this view is speculative since lipid utilization was not measured in the current 
study. 
Insulin Response to Estradiol and Exercise 
 Blood insulin concentration was measured pre-exercise, immediately post-exercise, 
and 30 minutes into recovery.  No significant differences were found when comparing blood 
insulin concentrations between phases or across time points during exercise.  Typically 
exercise is associated with a reduction in circulating insulin levels (4).  This did occur in the 
present study, as immediately post exercise and 30 minutes into recovery insulin 
concentrations were reduced from pre-exercise, but not to a level to reach statistical 
significance.  This lack of significance may be a function of a “basement effect” occurring 
within the data values (16).  That is, the initial pre-exercise concentrations of insulin were 
low enough that a further reduction below a minimum background level (i.e., basement level) 
was not physiologically possible or analytically detectable. 
These insulin findings are in agreement with some, but not all, studies as previous 
results are highly varied when looking at the effects of E2 and exercise on blood insulin 
concentration. For example, Horton et al. (12) reported a significant interaction effect 
between menstrual phase and time point during exercise.  Blood insulin concentration was 
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higher during the first 45 minutes of exercise in the mid-luteal phase when compared to the 
mid-follicular phase.  Campbell et al. (23) reported a significant main effect of exercise time 
on insulin concentration (decreasing) and, although not significant, these investigators also 
reported a tendency for blood insulin concentration to be higher in the luteal phase of the 
menstrual cycle (p = 0.07).  Lavoie et al. (13) also reported a significant decrease in insulin 
due to the main effect of exercise over time on insulin concentration (p < 0.01) in both the 
follicular and luteal phases of the menstrual cycle.  Although not reaching statistical 
significance, Lavoie et al. did observe a trend towards lower insulin concentration during the 
luteal phase of the menstrual cycle.  Bonen et al. (11) reported an opposite finding to Lavoie 
et al. (13), but somewhat similar to Campbell et al. (23), with slightly elevated levels of 
blood insulin concentration during the luteal phase of the menstrual cycle.  Regrettably, the 
current findings do not add any clarity to the issue of the influence of E2 and menstrual phase 
on insulin responses to exercise.  These mixed findings within studies suggest further 
research is needed and warranted on this topic. 
Insulin Percent Change 
 To determine if the added stress of exercise perhaps caused varying degrees of 
relative change in the insulin response during the different phases of the menstrual cycle, 
blood insulin concentration percent change was calculated between pre-exercise to 
immediately post-exercise and pre-exercise to 30 minutes into recovery.  This means of 
expressing the insulin data also resulted in no significant differences between phases or 
across time points during exercise.  Interestingly, all of the studies previously mentioned 
looked at the absolute insulin concentrations, and how concentrations were affected by 
varying levels of E2 and the stress of exercise (12, 13, 23).  It appears there have not been any 
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previous conducted menstrual cycle-exercise studies where insulin has been reported as 
calculated percent change. Obvious, the afore mentioned studies that did have significant 
absolute concentration changes would most likely have significant percent change responses 
too; and again, the current study data is at odds with some of these outcomes.  This 
dissimilarity in results may be due to dissimilarities in the methods used between the studies.  
In the present study, subjects were asked to exercise for 60 minutes and in the other studies 
subjects were asked to exercise for at least 90 minutes or more.  Methodology also differed 
on the acquisition of blood samples.  In the present study, blood was drawn pre-exercise, 
immediately post-exercise, and 30 minutes into recovery.  In the other studies discussed 
blood samples were taken pre-exercise and throughout the exercise bout, but not into 
recovery.  Therefore although insulin was being monitored in each of the studies, the points 
at which the information was gathered could change the interpretation of the results obtained 
(29). 
Conclusion 
It has been accepted that during rest E2 has both direct and indirect effects on energy 
metabolism (8).  There have only been a handful of studies investigating the relationship 
between E2 and exercise metabolism, specifically examining the key metabolic hormone 
insulin.  Horton et al. (12) showed that insulin was higher during exercise in the mid-luteal 
phase of the menstrual cycle when E2 is elevated.  Lavoie et al. (13) did not find significant 
difference in insulin levels during exercise after an overnight fast.  Hackney et al. (14) 
demonstrated that after a glucose load (oral glucose tolerance test; OGTT) insulin was 
significantly higher during the luteal phase of the menstrual cycle at rest and throughout 
exercise.  It is evident from even these few examples in some situations that a relationship 
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exists between E2, insulin, and exercise.  However, the current study suggests that varying 
levels of E2 brought about by normal hormonal fluctuations during the menstrual cycle do not 
have an effect on insulin during an acute bout of exercise. The methodologies for the studies 
that exist vary greatly between exercise modalities, intensities, length, diet restrictions, and 
when blood sampling occurred.  The results obtained in this study may not coincide with 
previous works due to these methodological differences.  The inconclusive nature of the 
present study and the contradictory findings in the research literature suggest that further 
research is warranted and should be conducted to allow for a greater understanding of exactly 
how E2 influences insulin during exercise. 
Hypothesis Outcomes 
Based on the findings of this study, the following indicates the acceptance of rejection 
of the research hypotheses: 
1. There is a significant difference in blood insulin levels during the mid-follicular 
phase when compared to blood insulin levels during the mid-luteal phase – 
Reject. 
a. Insulin concentration at baseline is significantly higher during the mid-
luteal phase compared to the mid-follicular phase – Reject. 
b. Insulin concentration immediately post exercise is significantly higher 
during the mid-luteal phase compared to the mid-follicular phase – Reject. 
c. Insulin concentration 30 minutes into recovery is significantly higher 
during the mid-luteal phase compared to the mid-follicular phase – Reject. 
2. The added stress of exercise did not cause a significant change in blood insulin 
levels when comparing insulin concentrations pre and post exercise during the 
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mid-follicular phase to insulin concentrations pre and post exercise during the 
mid-luteal phase – Accept. 
a. There is no significant percent change in insulin concentration between 
baseline and immediately post-exercise when comparing the mid-follicular 
phase to the mid-luteal phase – Accept. 
b. There is no significant percent change in insulin concentration between 
baseline and 30 minutes into recovery when comparing the mid-follicular 
phase to the mid-luteal phase – Accept. 
Study Limitations 
 There are several factors that directly influence the data within this study and are thus 
limitations to the research.  Diet and hydration status greatly effects insulin and unfortunately 
these factors varied greatly between the subjects, although each subject was instructed to 
repeat their exact diet-hydration practices for the 24 hours before each 60 minute exercise 
session.  To the knowledge of the investigator, all subjects complied with this request and 
indicated so when asked about compliance. 
 The insulin ELISA may not have been sensitive enough to capture the small, changes 
in insulin concentration since pre-exercise resting levels were very low.  This issue is always 
a possibility in biochemical assays, however, the ELISA used in this study was classified as 
an ultra-sensitive type by the manufacturer which in the realm of modern technology 
categorizes it as being able to measure the insulin hormone at the smallest detectable 
concentrations in humans.  Physiologically, it is also possible with the additional stress of 
exercise the insulin concentration (which normally decreases) could not decrease 
43 
 
substantially further since the levels started at the low end of concentrations found in the 
normal physiological range (i.e., basement effect). 
 Finally, it is certainly possible the sample size for this study was too small.  A power 
calculation on the observed absolute insulin concentrations and the changes observed 
suggested a β of approximately 0.36 was achieved and that an additional 14 subjects would 
have been necessary to reach the more typically accepted β value of 0.80.  Thus, the current 
study has to be viewed as underpowered statistically.  Although a power calculation was 
done prior to beginning the investigation, differences in study methodology may account for 
the differences in calculated β.  That is, the article used to calculate power compared insulin 
concentrations during exercise at differing phases of the menstrual cycle using a 
carbohydrate supplement or a placebo (18).  The current study did not use any 
supplementation.  In addition, the study used for the power calculation measured insulin 
concentration using a radioimmunoassay which may not have measured insulin 
concentrations as sensitively as the ELISA used in the current study.  These discrepancies in 
methodology between the two studies may account for why the current study was 
underpowered. 
Future Directions 
Future research should look at not only insulin during exercise but also glucagon in 
order to observe the influence E2 has on the Inulin/Glucagon ratio during exercise.  Insulin 
promotes glucose uptake and glycogen synthesis while glucagon promotes glycogenolysis 
and gluconeogenesis (4).  It has been demonstrated in animal models that E2 can cause a 
decrease in glucagon secretion (30).  Due to the antagonistic relationship of insulin and 
glucagon, the metabolic changes seen during exercise may be due to decreased glucagon 
44 
 
concentration which would mimic increased insulin concentration.  Research should also be 
performed with different populations including hormonal contraceptive users, persons with 
metabolic diseases, older pre-menopausal women, and post-menopausal women.  The 
information gathered incorporating such items may help to better explain the overall effects 
E2 has on insulin and exercise. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
45 
 
APPENDIX A: Indications for Terminating Exercise Testing 
Materials in appendices are not copyrighted to author – Cecily Lehman. 
 
Taken from: Whaley MH, Brubaker PH, Otto RM, editors. American College of Sports 
Medicine’s guidelines for exercise testing and prescription.  7thed.  Baltimore: Lippincott 
Williams & Wilkins; 2006.   
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APPENDIX B: Informed Consent 
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APPENDIX C: Medical History Questionnaire 
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APPENDIX D: Ovulation Kit Testing Protocol 
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APPENDIX E: Exercise Session Questionnaire 
 
Exercise Session Questionnaire 
Have you had anything to eat or drink, besides water, within the last 2 hours? 
Yes No 
Have you has any anti-inflammatory drugs (Advil, Tylenol, etc.) within the last 24 hours? 
Yes No 
Have you participated in any strenuous exercise within the last 24 hours? 
Yes No 
Have you had any caffeine or alcohol within the last 24 hours? 
Yes No 
Do you have your diet log? (Make a copy and give back to subject) 
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APPENDIX F: Estradiol ELISA Kit Protocol 
 
 
Estradiol (Human) 
 
ELISA Kit 
 
 
 
 
Catalog Number 
KA0234 96 assays 
 
Version: 03 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Intended for research use only 
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Introduction 
 
Intended  Use 
For the quantitative determination of Estradiol (E2) concentration in human serum. 
 
Background 
Estradiol (E2) is a C18 steroid hormone with a phenolic A ring. This steroid hormone has a 
molecular weight of 272.4. It is the most potent natural Estrogen, produced mainly by the 
ovary, placenta, and in smaller amounts by the adrenal cortex, and the male testes (1,2,3). 
 
Estradiol (E2) is secreted into the blood stream where 98% of it circulates bound to sex hormone binding 
globulin (SHBG). To a lesser extent it is bound to other serum proteins such as albumin. Only a tiny 
fraction circulates as free hormone or in the conjugated form (4,5). Estrogenic activity is effected via 
estradiol-receptor complexes which trigger the appropriate response at the nuclear level in the target 
sites. These sites include the follicles, uterus, breast, vagina, urethra, hypothalamus, pituitary and to a 
lesser extent the liver and skin. 
 
In non-pregnant women with normal menstrual cycles, estradiol secretion follows a cyclic, biphasic 
pattern with the highest concentration found immediately prior to ovulation (6,7). The rising 
estradiol concentration is understood to exert a positive feedback influence at the level of the 
pituitary where it influences the secretion of the gonadotropins, follicle stimulating hormone (FSH), 
and luteinizing hormone (LH), which are essential for follicular maturation and ovulation, 
respectively (8,9). Following ovulation, estradiol levels fall rapidly until the luteal cells become 
active resulting in a secondary gentle rise and plateau of estradiol in the luteal phase. During 
pregnancy, maternal serum Estradiol levels increase considerably, to well above the pre-ovulatory 
peak levels and high levels are sustained throughout pregnancy (10). 
 
Serum Estradiol measurements are a valuable index in evaluating a variety of menstrual 
dysfunctions such as precocious or delayed puberty in girls (11) and primary and secondary 
amenorrhea and menopause (12). Estradiol levels have been reported to be increased in 
patients with feminizing syndromes (14), gynaecomastia (15) and testicular tumors (16). 
 
sIn cases of infertility, serum Estradiol measurements are useful for monitoring induction of 
ovulation following treatment with, for example, clomiphene citrate, LH-releasing hormone 
(LH-RH), or exogenous gonadotropins (17,18). During ovarian hyperstimulation for in vitro 
fertilization (IVF), serum estradiol concentrations are usually monitored daily for optimal 
timing of human chorionic gonadotropin (hCG) administration and oocyte collection (19). 
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Principle  of  the  Assay 
The E2 EIA is based on the principle of competitive binding between E2 in the test specimen and E2-HRP 
conjugate for a constant amount of rabbit anti-Estradiol. In the incubation, goat anti-rabbit IgG-coated 
wells are incubated with 25 µl E2 standards, controls, patient samples, 100 µl Estradiol-HRP Conjugate 
Reagent and 50 µl rabbit anti-Estradiol reagent at room temperature (18-25°C) for 90 minutes. During the 
incubation, a fixed amount of HRP-labeled E2 competes with the endogenous E2 in the standard, 
sample, or quality control serum for a fixed number of binding sites of the specific E2 antibody. Thus, 
the amount of E2 peroxidase conjugate immunologically bound to the well progressively decreases as 
the concentration of E2 in the specimen increases. Unbound E2 peroxidase conjugate is then removed 
and the wells washed. Next, a solution of TMB Reagent is added and incubated at room temperature for 
20 minutes, resulting in the development of blue color. The color development is stopped with the 
addition of 1N HCl, and the absorbance is measured spectrophotometrically at 450 nm. The intensity of 
the color formed is proportional to the amount of enzyme present and is inversely related to the amount 
of unlabeled E2 in the sample. A standard curve is obtained by plotting the concentration of the standard 
versus the absorbance. The E2 concentration of the specimens and controls run concurrently with the 
standards can be calculated from the standard curve. 
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General  Information 
 
Materials  Supplied 
 
List of component  
Component Amount 
  
Goat Anti-Rabbit IgG-coated microtiter wells 96 wells 
  
Estradiol Reference Standards: 0, 10, 30, 100, 300, and 1000 pg/ml. Liquid, ready to use. 0.5 ml each 
  
Rabbit Anti-Estradiol Reagent (pink color) 7 ml 
  
Estradiol-HRP Conjugate Reagent (blue color) 12 ml 
  
Estradiol Control 1, Liquid, Ready to use 0.5 ml 
  
Estradiol Control 2, Liquid, Ready to use 0.5 ml 
  
TMB Reagent (One-Step) 11 ml 
  
Stop Solution (1N HCl) 11 ml 
  
 
Storage  Instruction 
Unopened test kits should be stored at 2-8°C upon receipt and the microtiter plate should be 
kept in a sealed bag with desiccants to minimize exposure to damp air. Opened test kits will 
remain stable until the expiration date shown, provided it is stored as described above. 
 
Materials  Required  but  Not  Supplied 
 
Precision pipettes: 25 µl , 50 µl, 100 µl, 200 µl, 
and 1.0 ml. Disposable pipette tips.  
 
Distilled and 
deionized water. 
Vortex mixer or 
equivalent. 
 
Absorbent paper or 
paper towel.Linear-
linear graph paper. 
 
A microtiter plate reader with a bandwidth of 10 nm or less and an optical density range 
of 0-3 O.D. at 450 nm wavelength is acceptable for use in absorbance measurement.  
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Precautions  for  Use 
1. Test methods are not available which can offer complete assurance that Hepatitis B 
virus, Human Immunodeficiency Virus (HIV/HTLV-III/LAV), or other infectious agents are 
absent from the reagents in this kit. Therefore, all human blood products, including 
patient samples, should be considered potentially infectious. Handling and disposal 
should be in accordance with the procedures defined by an appropriate national 
biohazard safety guideline or regulation, where it exists (e.g., USA Center for Disease 
Control/National Institute of Health Manual, “Biosafety in Microbiological and 
Biomedical Laboratories,” 1984)(22).  
 
2. Reliable and reproducible results will be obtained when the assay procedure is carried 
out with a complete understanding of the package insert instructions and with 
adherence to good laboratory practice.  
 
3. The wash procedure is critical. Insufficient washing will result in poor precision and 
falsely elevated absorbance readings.  
 
4. Serum samples demonstrating gross lipemia, gross hemolysis, or turbidity should not 
be used with this test.  
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Assay Protocol 
Sample  Preparation 
1. Only human serum should be used.  
 
2. No special pretreatment of sample is necessary.  
 
3. Serum samples may be stored at 2-8°C for up to 24 hours, and should be frozen at 
−10°C or lower for longer periods. Do not use grossly hemolyzed or grossly lipemic 
specimens.  
 
4. Please note: Samples containing sodium azide should not be used in the assay.  
 
5. Samples with expected Estradiol concentrations over 1000 ng/ml may be quantitated by 
dilution with diluent available from Abnova, Inc.  
Assay  Procedure 
1. All reagents should be brought to room temperature (18-25°C) before use.  
 
2. Secure the desired number of coated wells in the holder.  
 
3. Dispense 25 µl of standards, specimens and controls into appropriate wells.  
 
4. Dispense 100 µl of Estradiol-HRP Conjugate Reagent into each well.  
 
5. Dispense 50 µl of rabbit anti-Estradiol(E2) reagent to each well.  
 
6. Thoroughly mix for 30 seconds. It is very important to mix them completely.  
 
7. Incubate at room temperature (18-25°C) for 90 minutes.  
 
8. Rinse and flick the microwells 5 times with distilled or deionized water. (Please do not use tap 
water.)  
 
9. Dispense 100 µl of TMB Reagent into each well. Gently mix for 10 seconds.  
 
10. Incubate at room temperature (18-25°C) for 20 minutes.  
 
11. Stop the reaction by adding 100 µl of Stop Solution to each well.  
 
12. Gently mix 30 seconds. It is important to make sure that all the blue color changes to 
yellow color completely.  
 
13. Read absorbance at 450 nm with a microtiter well reader within 15 minutes.  
 
  Quality  Control 
 
Good laboratory practice requires that controls are run with each calibration curve. A 
statistically significant number of controls should be assayed to establish mean values and 
acceptable ranges to assure proper performance. We recommend using Bio-Rad Lyphochek 
Immunoassay Control Sera as controls. Abnova Estradiol EIA kit also provides with internal 
controls, Level 1 and 2. 
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Data  Analysis 
 
Calculation  of  Results 
1. Calculate the mean absorbance value (A450) for each set of reference standards, controls and 
samples.  
 
2. Construct a standard curve by plotting the mean absorbance obtained for each 
reference standard against its concentration in pg/ml on a linear-linear graph paper, 
with absorbance values on the vertical or Y axis, and concentrations on the horizontal 
or X axis.  
 
3. Use the mean absorbance values for each specimen to determine the corresponding 
concentration of Estradiol in pg/ml from the standard curve.  
 
4. Any values obtained for diluted samples must be further converted by applying the 
appropriate dilution factor in the calculations.  
 
  Example  of  Standard  Curve 
 
Results of a typical standard run with optical density readings at 450 nm shown in the Y axis 
against Estradiol concentrations shown in the X axis. Note: This standard curve is for the 
purpose of illustration only, and should not be used to calculate unknowns. Each laboratory 
must provide its own data and standard curve in each experiment.  
Estradiol (pg/ml) Absorbance (450 nm) 
  
0 2.943 
  
10 2.551 
  
30 2.055 
  
100 1.624 
  
300 0.925 
  
1000 0.571 
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Expected  Values  and  Sensitivity 
 
Each laboratory should establish its own normal range based on the patient population. 
Abnova Estradiol EIA was performed on randomly selected outpatient clinical laboratory 
samples. The results of these determinations are as follows: 
 
Males:   < 60 pg/ml 
Females: postmenopausal phase < 18 pg/ml 
 ovulating, early follicular 30-100 pg/ml 
  late follicular 100-400 pg/ml 
  luteal phase 60-150 pg/ml 
 pregnant, normal up to 35,000 pg/ml 
 prepubertal children, normal < 10 pg/ml 
 
 
Performance  Characteristics 
  Sensitivity 
 
The minimum detectable concentration of the Abnova Estradiol ELISA assay as measured by 
2 SD from the mean of a zero standard is estimated to be 10 pg/ml.. 
  Specificity 
 
The following materials have been checked for cross reactivity. The percentage indicates 
cross reactivity at 50% displacement compared to Estradiol.  
 
Data on the cross-reactivity for several endogenous and pharmaceutical steroids are 
summarized in the following table:  
 
Cross-reactivity (%) = Observed Estradiol Concentration / Steroid Concentration × 100.   
Steroid Cross-Reactivity 
  
Estradiol 100% 
  
Estrone 2.10% 
  
Estriol 1.50% 
  
17a Estradiol 0.30% 
  
Cortisol <0.01% 
  
Cortisone <0.01% 
  
Progesterone <0.01% 
  
Testosterone <0.01% 
  
DHEA-Sulphate <0.01% 
  
5a-Dihydrotestosterone <0.01% 
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Precision 
 
Within-run precision was determined by replicate determinations of four different serum 
samples in one assay. Within-assay variability is shown below:  
Samples 1 2 3 4 
     
# Replicates 24 24 24 24 
     
Mean Estradiol (pg/ml) 13 73 247 633 
     
S.D. 3 7 10 31 
     
C.V. (%) 24.1 10.3 4.1 4.9 
     
 
 
Between-run precision was determined by replicate measurements of six different serum 
samples over a series of individually calibrated assays. Between-assay variability is shown 
below:  
Samples 1 2 3 4 
     
# Replicates 20 20 20 20 
     
Mean Estradiol (pg/ml) 14 82 264 691 
     
S.D. 4 8 17 45 
     
C.V. (%) 26.7 10.3 6.4 6.6 
     
 
  Spiking  Recovery 
 
Various patient serum samples of known Estradiol levels were combined and assayed in 
duplicate. The mean recovery was 101.3%.  
PAIR NO. EXPECTED [Estradiol] (pg/ml) OBSERVED [Estradiol] (pg/ml) % RECOVERY 
    
1 580 599 103.3 
    
2 810 733 90.4 
    
3 280 249 89.2 
    
4 265 285 107.5 
    
5 81 91 112.6 
    
6 62 67 107.3 
    
7 18 18 98.7 
    
 
 
 
 
 
 
 
 
 
 
 
 
74 
 
Resources 
References 
Tsang,   B.K.,   Armstrong,   D.T.   and   Whitfield,   J.F.,   Steroid   biosynthesis   by   isolated   
human   ovarian Follicular cells in vitro, J. Clin. Endocrinol.Metab., 1980; 51: 1407-1411. 
 
Gore-Langton, R.E. and Armstrong, D.T., Follicular steroidogenesis and its control. In: Knobil, E., 
and Neill, J. et al., ed. The Physiology of Reproduction. Raven Press, New York; 1988: 331-385.  
 
Hall, P.F., Testicular steroid synthesis: Organization and regulation. In: Knobil, E., and Neill, J. et 
al., ed. The Physiology of Reproduction. Raven Press, New York; 1988: 975-998.  
 
Siiteri, P.K., Murai, J.T., Hammond, G.L., Nisker, J.A., Raymoure, W.J. and Kuhn, R.W., The serum 
transport of steroid hormones, Rec. Prog. Horm. Res., 1982; 38: 457-510.  
 
Baird, D.T., Ovarian steroid secretion and metabolism in women. In: James, V.H.T., Serio, M. and 
Giusti, G., eds. The Endocrine Function of the Human Ovary. Academic Press, New York; 1976: 
125-133.  
 
McNatty, K.P., Baird, D.T., Bolton, A., Chambers, P., Corker, C.S. and McLean, H., Concentration of 
oestrogens and androgens in human ovarian venous plasma and follicular fluid throughout the 
menstrual cycle, J. Endocrinol., 1976; 71: 77-85.  
 
Abraham, G.E., Odell, W.D., Swerdloff, R.S., and Hopper, K., Simultaneous radioimmunoassay of 
plasma FSH, LH, progesterone, 17-hydroxyprogesterone and estradiol-17β during the menstrual 
cycle,  
 
J. Clin. Endocrinol.Metab., 1972; 34: 312-318.  
 
March, C.M., Goebelsmann, U., Nakumara, R.M., and Mishell, D.R. Jr., Roles of estradiol and 
progesterone in eliciting the midcycle luteinizing hormone and follicle-stimulating hormone 
surges. J. Clin. Endocrinol.Metab., 1979; 49: 507-513.  
 
Simpson, E.R., and MacDonald, P.C., Endocrinology of pregnancy. n: Williams, R.H., ed., Textbook 
of Endocrinology. Saunders Company, Philadelphia; 1981: 412-422.  
 
Jenner, M.R., Kelch, R.P., Kaplan, S.L. and Grumbach, M.M., Hormonal changes in puberty: IV. 
Plasma estradiol, LH, and FSH in prepubertal children, pubertal females and in precocious 
puberty, premature thelarche, hypogonadism and in a child with feminizing ovarian tumor. J. Clin. 
Endocrinol.Metab., 197 2; 34: 521-530.  
 
Goldstein, D., Zuckerman, H., Harpaz, S., et al., Correlation between estradiol and progesterone in 
cycles with luteal phase deficiency.Fertil.Steril., 1982; 37: 348-354.  
 
Kirschner, M.A., The role of hormones in the etiology of human breast cancer. Cancer, 1977; 39: 
2716-2726.  
 
Odell, W.D. and Swerdloff, R.S., Abnormalities of gonadal function in men. Clin.Endocr., 1978; 8: 
149-180.  
 
MacDonald, P.C., Madden, J.D., Brenner, P.F., Wilson, J.D. and Siiteri, P.K., Origin of estrogen in 
normal men and in women with testicular feminization, J.Clin. Endocrinol.Metabl., 1979; 49: 905-
916.  
 
 
 
75 
 
Fishel, S.B., Edwards, R.G., Purdy, J.M., Steptoe, P.C., Webster, J., Walters, E., Cohen, J., 
Fehilly, C. Hewitt, J., and Rowland, G., Implantation, abortion and birth after in vitro 
fertilization using the natural menstrual cycle or follicular stimulation with clomiphene citrate 
and human menopausal gonadotropin, J. In Vitro Fertil. Embryo Transfer, 1985; 2: 123-131.  
 
Ratcliffe, W.A., Carter, G.D., Dowsett, M., et al., Oestradiol assays: applications and guidelines 
for the provision of a clinical biochemistry service, Ann. Clin. Biochem., 1988; 25:466-483.  
 
Tietz, N.W. ed., Clinical Guide to Laboratory Tests, 3rd Edition, W.B. Saunders, Co., 
Philadelphia, 1995: 216-217.  
 
USA Center for Disease Control/National Institute of Health Manual, “Biosafety in 
Microbiological and Biomedical Laboratories”, 1984. 
 
ICN Guide to Endocrine Testing. Diagnostic Division, ICN Biomedicals, Inc. pp. 2:15-19. T C  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
76 
 
APPENDIX G: Insulin ELISA Kit Protocol  
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Introduction  and  Background 
 
A.     Overview 
 
Insulin is the principal hormone responsible for the control of glucose metabolism. It is 
synthesized in the ß-cells of the islets of Langerhans as the precursor, proinsulin, which is 
processed to form C-peptide and insulin. Both are secreted in equimolar amounts into the 
portal circulation. The mature insulin molecule comprises two polypeptide chains, the A chain 
and B chain (21 and 30 amino acids respectively). The two chains are linked together by two 
inter-chain disulphide bridges. There is also an intra-chain disulphide bridge in the A chain. 
Insulin concentrations are severely reduced in insulin-dependent diabetes mellitus (IDDM) and 
some other conditions such as hypopituitarism. Insulin levels are raised in non-insulin-
dependent diabetes mellitus (NIDDM), obesity, insulinoma and some endocrine dysfunctions 
such as Cushing’s syndrome and acromegaly. 
B.     Test  Principle 
 
The Insulin ELISA is a solid phase two-site enzyme immunoassay. It is based on the direct 
sandwich technique in which two monoclonal antibodies are directed against separate antigenic 
determinants on the insulin molecule. During incubation insulin in the sample reacts with enzyme 
(HRP)-conjugated anti-insulin antibody and anti-insulin antibody bound to micro-titration well. A 
simple washing step removes unbound enzyme labeled antibody. The bound HRP complex is 
detected by reaction with TMB substrate. The reaction is stopped by adding acid to give a 
colorimetric endpoint that is read using ELISA reader. 
C.     Notice  for Application  of  Kit  
This kit has been configured for research use only and is not for diagnostic and clinical use. 
 
D.     Application  
The Insulin ELISA Kit is intended for the quantitative measurement Insulin in human serum or 
plasma. 
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Material  and  Method  
A. List  of  component  
  96  Tests 
Microwells coated with Insulin MAb 12x8x1 
Insulin Standard 1:1 vial (Ready to use) 2 ml 
Insulin Standards 2-6: 5 vials (Ready to use) 1 ml 
Insulin Enzyme Conjugate: 1 vial 1 ml 
Assay Diluent: 1 bottle (Ready to use) 14 ml 
TMB Substrate: 1 bottle (Ready to use) 12 ml 
Stop Solution: 1 bottle (Ready to use) 12 ml 
20X Wash concentrate: 1 bottle 25 ml 
 
 
B. Additional  Required  Materials  But  Not  Provided  
1. Distilled or deionized water  
 
2. Precision pipettes  
 
3. Disposable pipette tips  
 
4. ELISA reader capable of reading absorbance at 450nm   
5. Absorbance paper or paper towel  
 
6. Graph paper  
 
 
C. Stability  and  Storage  
 
1. Store the kit at 2-8°C.  
 
2. Keep microwells sealed in a dry bag with desiccants.  
 
3. The reagents are stable until expiration of the kit.  
 
4. Do not expose reagent to heat, sun, or strong light.  
 
 
D. Warnings  and  Precautions  for  Users  
 
1. Potential biohazardous materials:  
 
The calibrator and controls contain human source components, which have been tested 
and found non-reactive for hepatitis B surface antigen as well as HIV antibody with FDA 
licensed reagents. However there is no test method that can offer complete assurance 
that HIV, Hepatitis B virus or other infectious agents are absent. These reagents should 
be handled at the Biosafety Level 2, as recommended in the Centers for Disease 
Control/National Institutes of Health manual, "Biosafety in Microbiological and 
Biomedical Laboratories" 1984.  
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2. This test kit is USA FDA exempt product.  
 
3. Do not pipette by mouth. Do not smoke, eat, or drink in the areas in which specimens or 
kit reagents are handled.  
4. The components in this kit are intended for use as an integral unit. The components of 
different lots should not be mixed.  
 
5. It is recommended that standards, control and serum samples be run in duplicate.  
 
6. Optimal results will be obtained by strict adherence to the test protocol. Accurate and 
precise pipetting as following the exact time and temperature requirements prescribed 
are essential. Any deviation from this may yield invalid data.  
 
E. Specimen  Collection  and  Handling  
1. Collect blood specimens and separate the serum immediately.  
 
2. Specimens may be stored refrigerated at (2-8°C) for 5 days. If storage time exceeds 5 
days, store frozen at (-20°C) for up to one month.  
 
3. Avoid multiple freeze-thaw cycles.  
 
4. Prior to assay, frozen sera should be completely thawed and mixed well.  
 
5. Do not use grossly lipemic specimens.  
 
 
F. Reagent  Preparation  and  Storage 
 
1. 20X Enzyme Conjugate: Prepare 1X working dilution at 1:20 with assay diluent as 
needed, e.g. 0.1 ml of the stock conjugate in 1.9 ml of assay diluent is sufficient for 20 
wells. The diluted conjugate has to be used the same day.  
 
2. 20X Wash Buffer Concentrate: Prepare 1X wash buffer by adding the contents of the 
bottle to 475 ml of distilled water. Store 1X wash buffer at room temperature.  
 
 
G. Protocol  
Prior to assay, allow reagents to stand at room temperature. Gently mix all reagents before 
use.  
1. Place the desired number of coated strips into the holder.  
 
2. Pipette 25 µl of Insulin standards, control and patient’s sera into appropriate wells.  
 
3. Add 100 µl of working Insulin Enzyme Conjugate to all wells.  
 
4. Thoroughly mix for 10 sec., it is important to have a complete mixing in this step.  
 
5. Incubate for 60 minutes at room temperature (18-26°C).  
 
6. Remove liquid from all wells. Wash wells three times with 300 µl of 1X wash buffer. Blot 
on absorbent paper towels.  
 
7. Add 100 µl of TMB substrate to all wells.  
 
80 
 
8. Incubate for 15 minutes at room temperature.  
 
9. Add 50 µl of stop solution to all wells. Shake the plate gently to mix the solution.  
 
10. Read absorbance on ELISA Reader at 450 nm within 15 minutes after adding the stopping 
solution.  
 
 
Calculation  of  Results  
The standard curve is constructed as follows: 
 
1. Check Insulin standard value on each standard vial. This value might vary from lot to 
lot. Make sure you check the value on every kit.  
 
2. To construct the standard curve, plot the absorbance for the insulin standards (vertical 
axis) versus the insulin standard concentrations in µIU/ml (horizontal axis) on a linear 
graph paper. Draw the best curve through the points.  
 
3. Read the absorbance for controls and each unknown sample from the curve. Record the 
value for each control or unknown sample.  
 
4. Value above the highest point of the standard are retested after diluting with “0” 
standard.  
 
 
Example  of  Standard  Curve 
 
 
 OD 450 nm Conc. µIU/mL 
   
Standard 1 0.05 0 
   
Standard 2 0.11 6.25 
   
Standard 3 0.22 12.5 
   
Standard 4 0.49 25 
   
Standard 5 1.00 50 
   
Standard 6 2.11 100 
   
 
 
Expected  Values 
 
It is strongly recommended that each laboratory should determine its own normal and abnormal 
values. 
 
In a study conducted with apparently normal healthy adults, using the Insulin ELISA the 
following values are observed: < 25 µlU/ml. 
 
 
Limitation  of  the  Test 
 
1. The test results obtained using this kit serve only as an aid to diagnosis and should be 
interpreted in relation to the patient’s history, physical findings and other diagnostic 
procedures.  
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2. Do not use sodium azide as preservative. Sodium azide inhibits HRP enzyme activities.  
 
 
Performance  Characteristics 
 
1. Correlation with a Reference ELISA kit:  
A total of 62 sera were tested by this ELISA and a reference ELISA kit. Results were as 
follows: 
 
 
Correlation Slope Intercept 
   
0.91 0.80 0.24 
   
 
2. Precision  
 
a.     Intra-Assay   
Sample  No. of Replicates Mean µIU/ml Standard Deviation Coefficient of Variation (%) 
       
 1  10 9.26 0.58 6.3 
       
 2  10 7.01 0.57 8.1 
       
 b. Inter-Assay    
     
Sample  No. of Replicates Mean µIU/ml Standard Deviation Coefficient of Variation (%) 
       
 1  10 6.79 0.58 8.5 
       
 2  10 9.27 0.69 7.4 
      
3. Linearity    
 
Two different patient samples were diluted with the "0" calibrator to 1:2, 1:4, 1:8. Insulin values were 
assayed and results were corrected with the dilution factor. The results of these dilution tests are as 
follows: 
 Original Value  Percentage of Recovery  
      
 Serum (µIU/ml) 1/2  1/4  1/8 
        
 1 30 95.1  91.5  88.6 
        
 2 71 106  95.5  105 
        
4. Sensitivity     
 
The sensitivity was determined by calculating the mean plus 2SD of the standard zero point 
tested 20 times in the same run.  
Serum No. of Replicates Mean (µIU/ml) Standard Deviation Mean + 2SD (Sensitivity) 
     
Zero Standard 20 0.477 0.495 1.467 
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5. Specificity 
 
The antibodies employed in this kit cross react with bovine insulin (20-25%) and porcine 
insulin but not with proinsulin of any species or any other insulin complexes. 
 
 
6. Recovery  
Samples have been spiked by adding Insulin solutions with known concentrations in a 1:1 
ratio. 
 
 
Expected value (µIU/ml) Recovered (µIU/ml) Percentage of Recovery 
   
9.85 8.80 89.3 
   
41.1 40.4 98.3 
   
53.7 54.2 100.9 
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